Sek Kathiresan MD
@skathire
CEO @VerveTx $VERV; Imagine if a one-time treatment led to permanent lowering of LDL cholesterol: that’s what we are developing to treat heart attack
The PCSK9 gene is a key regulator of cholesterol in the liver. At Verve, we are developing VERVE-102, a single-course #geneediting medicine, designed to permanently turn off the PCSK9 gene in the liver to reduce blood LDL-C, (also known as the “bad cholesterol”) levels in people…
Today, we are thrilled to announce that @VerveTx has entered into a definitive agreement to be acquired by @EliLillyandCo From 2018 to 2025, Verve moved a new concept (a one-dose future for the treatment of atherosclerotic cardiovascular disease) and a new medical technology (in…
Happy Father’s Day to all the Dads Sure am proud of my crew! Cc: @ninakathiresan
We're excited to announce that Claire Mazumdar has been appointed to our Board of Directors. As CEO of @BicaraTx, Claire's expertise and perspective as the leader of a late-stage clinical biotech will complement our board well. Welcome, Claire!
So exciting when different agents from different companies each targeting same new pathway all lead to consistent clinical results APRIL protein as a target, IgA nephropathy as an indication, proteinuria reduction as outcome
Otsuka tops Vera Therapeutics $VERA in kidney disease study showdown statnews.com/2025/06/06/ots…
"Genetic therapy is frankly a game changer," said Nissen. Instead of a lifetime of statins and PCSK9 treatments for a young person with inherited high cholesterol, a one-and-done DNA edit could knock out the troublesome gene altogether. @VerveTx $VERV barrons.com/articles/strok…
Dad and Mom (@Penn '92) Dad and Daughter (@Penn '25) Congratulations @ninakathiresan! So proud of you and super excited for your path ahead.
Congratulations to @kiranmusunuru and Team on this terrific work to create a bespoke adenine base editor to help a baby. Remarkable story of translation of science to clinical impact. I am particularly proud as Kiran was the first research trainee (post-doctoral fellow) in my…
CRISPR is used in landmark treatment to correct genetic misspelling of a single patient statnews.com/2025/05/15/cri… via @Jasonmmast
The LDL Cumulative Exposure Hypothesis The longer your arteries are exposed to high LDL-C, the ⬆️ the risk of atherosclerosis. 📈 🔬 Early & sustained LDL lowering = lifelong CV benefit. 🔗 nature.com/articles/s4156… #CardioTwitter #MedTwitter #FOAMed #MedED @ACCinTouch…
Whilst we wait for the results of the inclisiran CVOTs this analysis led by Benoit Arsenault using instrument variables to mimic hepatic and circulating pcsk9 suggests it’s all proportional to atherogenic lipid change #hope track.smtpsendmail.com/9032119/c?p=z3…
Honored, humbled and excited to become the inaugural Chair of @MassGenBrigham Department of Medicine @MGHMedicine @BrighamWomens. Grateful to continue working with Bruce Levy and Colleen Curry in a unified Department as we navigate tumultuous waters ahead. AMCs have a future!
Our team had a wonderful time at the #EASCongress2025 presenting recent highlights from our PCSK9 program and Verve’s vision of a one dose future to address #cardiovasculardisease. View the EAS presentation here: vervetx.com/sites/default/…
8/Cantor’s pricing model for a one-time therapy falls in the range of 5x to 10x of the annual standard care cost. That means that $VERV-102 expected pricing range will be between ~$18,600 & ~$70,000 per dose. That means that even at the lowest target price - VERVE-102's projected…